Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax offers a Therapeutic Strategy for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR+VEN), curren...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Eide, Christopher A., Kurtz, Stephen E., Kaempf, Andy, Long, Nicola, Agarwal, Anupriya, Tognon, Cristina E., Mori, Motomi, Druker, Brian J., Chang, Bill H., Danilov, Alexey V., Tyner, Jeffrey W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484148/
https://ncbi.nlm.nih.gov/pubmed/32094466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0764-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados